Facultad de Ciencias del Deporte
Cáceres, 10003, Spain
NCT Number: NCT05266989
People with fibromyalgia could experience physical and cognitive impairment as well as higher dual-task cost than healthy people when two tasks are performed simultaneously. Transcranial direct current stimulation is a promising non-pharmacological therapy. However, there is insufficient evidence about the intensities dose-response. Therefore, this protocol aims to 1) to compare the effectiveness and the impact of two tDCS intensities (1mA and 2mA) on cognitive, motor, brain functions, and cardiac autonomic modulation; 2) to study the impact of tDCS on the dual-task performance and creativity after applying tDCS in the dorsolateral prefrontal cortex. As hypotheses, a reduction of cognitive-motor interference in dual-task performance and also a modification in neurophysiological parameters, and an improvement in cardiac autonomic modulation are expected. Finally, no different effects are obtained depending on the intensity applied.
Looking for future studies?
Notify Me30 year–75 year
Female
Observational
Cáceres, 10003, Spain
Fibromyalgia is characterized by widespread pain and other associated symptoms, including stiffness, fatigue, non-recovery sleep, anxiety, or depression. On a physical level, people with FM frequently suffer from a sedentary state which reduces cardiovascular fitness and leads to mobility, strength and balance impairments. On a cognitive level, people with FM have often impaired cognitive functions such as memory, attention, processing speed, and executive functions. As a result of all of these symptoms, people with FM have a decreased performance in activities of daily living that are commonly presented as a simultaneous execution of two or more task at the same time (dual-task; DT).
To the knowledge of the investigators, no studies have focused on the application of transcranial direct current stimulation (tDCS) on the dorsolateral prefrontal cortex (DLPFC) to reduce the interference in DT performance. Furthermore, there are no studies that have studied the effects of different intensities of tDCS on DLPFC in people with FM in DT performance. Similarly, there are no studies that have focused on describing how neurophysiological variables may be modified in people with FM during DT performance. Therefore, it seems interesting to know how tDCS can influence these types of variables in order to improve the quality of life of this population and to open new frontiers for research.
The hypotheses that are proposed for this study are as follows: a) the application of tDCS will improve physical performance in physical variables that will be measured through balance and strength tasks; b) the application of tDCS will improve performance on neurophysiological variables that will be measured through brain electrical activity and HRV; c) the application of tDCS will improve performance in DT conditions as well as in creativity tasks; d) tDCS will have different effects depending on the variability of fibromyalgia symptoms presented (pain, sleep problems and depression); e) no significant effects on the variables would be expected depending on the type of tDCS intensity applied.
At this point, the main objectives of this protocol are: 1) to compare the effectiveness and the impact of two tDCS intensities (1mA and 2mA) on neurophysiological variables, cognitive, and motor functions; 2) to study the impact of tDCS on the dual-task performance and creativity after applying tDCS in dorsolateral prefrontal cortex.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Non-invasive technique that modulates the excitability of the cortex by applying low-intensity current
Time frame: Once before and after each tDCS session
The Enobio instrument (Neuroelectrics) and Neuroelectrics instrument driver software (NIC1) will be used to record EEG. Theta, alpha and beta power spectrums will be extracted from a 5 minute recording.
Time frame: Once before and after each tDCS session
The Enobio instrument (Neuroelectrics) and Neuroelectrics instrument driver software (NIC1) will be used to record HRV. Time domain (SDNN, RMSSD, RR-interval and pNN50), frequency domain (LFnu, HFnu, LF/HF and total power) and non-linear measures (SampEn, SD1 and SD2) will be extracted from a 5 minute recording.
Time frame: Once before and after each tDCS session
The tests will be static position with eyes open and static position with eyes closed. The test will be performed on a Kistler force platform.
Time frame: Once before and after each tDCS session
The execution of the test consists of performing a concentric contraction of knee flexion and extension six times consecutively and without pause between repetitions at a speed of 60 /s and in a range of movement from 0 to 90 degrees, being 0 full extension and 90 flexion. The test will be performed on the isokinetic dynamometer Multi-Joint 3, Biodex Medical Sistems.
Time frame: Once before and after each tDCS session
Participants will simultaneously perform the balance test (static position with eyes open and static position with eyes closed) and a cognitive task. The cognitive task will consist of two-by-two substractions from a number greater than 100.
Time frame: Once before and after each tDCS session
Participants will simultaneously perform the strenght test (conducting a concentric contraction of knee flexion and extension six times consecutively and without pause between repetitions at a speed of 60 /s and in a range of movement from 0 to 90 degrees, being 0 full extension and 90 flexion) and a cognitive task. The cognitive task will consist of two-by-two substractions from a number greater than 100.
Time frame: At week 1
Age, level of education, injuries, or falls in the last few months, as well as other health related information, will be asked.
Time frame: At week 1
International Physical activity Questionnaire (IPAQ): results can be reported in categories (low activity levels, moderate activity levels or high activity levels) or as a continuous variable (MET minutes a week). MET minutes represent the amount of energy expended carrying out physical activity. Scoring a low level of physical activity on the IPAQ means that you are not meeting any of the criteria for either moderate or high levels of physical activity.
Time frame: At week 1
Fibromialgia Impact Questionnaire Revised (FIQ-R): the minimum score is 0 and the maximum is 100, corresponding to the worst overall symptom impact.
Time frame: At week 1
Falls Efficacy Scale International (FES-I): the minimum score is 16 and the maximum is 64. The higher the score, the greater the fear of falling.
Time frame: At week 1
EuroQol- 5 dimensions- 5 levels (EQ-5D-5L) (range 0 to 100 with higher values corresponding to better health status).
Time frame: At week 1
Pittsburg Sleep Quality Index (PSQI) (range 0 to 21, with higher score referring to worse sleep quality).
Time frame: At week 1
Montreal Cognitive Assessment (MoCA) (range 0 to 35 with higher values corresponding to better cognitive function).
Time frame: Once after the tDCS sessions
Survey of sensations related to tDCS
Time frame: At week 1
Body composition will be measured with the Tanita BC-418 Body Composition Analyzer
Time frame: At week 1
Using a SECA 285 model.
University of Extremadura
Other
Effects of Transcranial Direct Current Stimulation on Brain Electrical Activity, Heart Rate Variability, and Dual-Task Performance in Healthy and Fibromyalgia Women
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05998369
Abdominal Pain, Autonomic Nervous System Diseases
Palo Alto, California, United States
View Trial DetailsNCT06752590
Fibromyalgia, Muscular Diseases
Nagakute, Aichi-ken, Japan
View Trial DetailsNCT05237050
Chronic Pain, Fibromyalgia
Gap, Hautes Alpes, France
View Trial DetailsNCT07665411
Fibromyalgia, Muscular Diseases
Covilha, Castelo Branco District, Portugal
View Trial Details